209 related articles for article (PubMed ID: 8383541)
1. Chemotherapy for minimally differentiated acute myeloid leukemia (AML-M0). A report on five cases and review of the literature.
Yokose N; Ogata K; Ito T; Miyake K; An E; Inokuchi K; Yamada T; Gomi S; Tanabe Y; Ohki I
Ann Hematol; 1993 Feb; 66(2):67-70. PubMed ID: 8383541
[TBL] [Abstract][Full Text] [Related]
2. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).
Ohno R; Kobayashi T; Morishima Y; Hiraoka A; Imai K; Asoh N; Tsubaki K; Tomonaga M; Takahashi I; Kodera K
Leukemia; 1992; 6 Suppl 2():92-5. PubMed ID: 1578954
[TBL] [Abstract][Full Text] [Related]
3. [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
Fujiwara M; Satou N; Izumi N; Shibasaki Y; Higashimura M; Tsukada N; Koike T
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1793-8. PubMed ID: 18030012
[TBL] [Abstract][Full Text] [Related]
4. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group.
Kanamaru A; Takemoto Y; Tanimoto M; Murakami H; Asou N; Kobayashi T; Kuriyama K; Ohmoto E; Sakamaki H; Tsubaki K
Blood; 1995 Mar; 85(5):1202-6. PubMed ID: 7858250
[TBL] [Abstract][Full Text] [Related]
5. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
Kobayashi T; Miyawaki S; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Ohmoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Matsuoka A; Tomonaga M; Ohno R
J Clin Oncol; 1996 Jan; 14(1):204-13. PubMed ID: 8558199
[TBL] [Abstract][Full Text] [Related]
6. Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.
Ohno R; Kato Y; Nagura E; Murase T; Okumura M; Yamada H; Ogura M; Minami S; Suzuki H; Morishima Y
J Clin Oncol; 1986 Dec; 4(12):1740-7. PubMed ID: 3465875
[TBL] [Abstract][Full Text] [Related]
7. Behenoyl cytosine arabinoside, aclacinomycin A, 6-mercaptopurine, and prednisolone combination therapy for acute non-lymphocytic leukaemia in adults.
Yoshida M; Suda K; Tsuboyama A; Sasaki R; Kitagawa S; Kano Y; Muto Y; Takaku F; Sakamoto S; Miura Y
Eur J Haematol; 1989 Jul; 43(1):1-6. PubMed ID: 2767238
[TBL] [Abstract][Full Text] [Related]
8. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
Miyawaki S; Tanimoto M; Kobayashi T; Minami S; Tamura J; Omoto E; Kuriyama K; Hatake K; Saito K; Kanamaru A; Oh H; Ohtake S; Asou N; Sakamaki H; Yamada O; Jinnai I; Tsubaki K; Takeyama K; Hiraoka A; Matsuda S; Takahashi M; Shimazaki C; Adachi K; Kageyama S; Ohno R
Int J Hematol; 1999 Aug; 70(2):97-104. PubMed ID: 10497848
[TBL] [Abstract][Full Text] [Related]
9. [Acute myelogenous leukemia with diabetes insipidus without desmopression administration by anti-leukemic chemotherapy].
Ino Y; Tsurumi H; Yamada T; Murakami N; Moriwaki H; Muto Y
Rinsho Ketsueki; 1995 Dec; 36(12):1359-64. PubMed ID: 8587172
[TBL] [Abstract][Full Text] [Related]
10. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of acute myelogenous leukemia in patients more than 80 years old].
Takeyama H; Yamamoto Y; Miyata Y; Yamada H; Watanabe E; Aoki H; Iinuma M
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1089-93. PubMed ID: 9239161
[TBL] [Abstract][Full Text] [Related]
12. [Cancer curable by chemotherapy: acute myelogenous leukemia].
Ohno R; Tanimoto M; Morishita Y; Morishima Y; Saito H; Yokomaku S; Nagai T; Kodera Y; Minami S
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1329-34. PubMed ID: 2730046
[TBL] [Abstract][Full Text] [Related]
13. [A case of acute nonlymphocytic leukemia with leukemic cell infiltration to the uterus followed by bone marrow relapse].
Shiga Y; Shichishima T; Aikawa K; Gotoh J; Furukawa T; Yamagiwa A; Ishibashi T; Maruyama Y
Rinsho Ketsueki; 1994 May; 35(5):501-5. PubMed ID: 8028198
[TBL] [Abstract][Full Text] [Related]
14. [A randomized trial of conventional dose vs reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients].
Mori M; Nisimura H; Urabe A; Tamura K; Makino S; Okabe K; Tomiyama J; Hara M; Tanimoto M; Kikuchi M; Hamaguchi H; Sato H; Saburi Y
Rinsho Ketsueki; 2000 Feb; 41(2):109-14. PubMed ID: 10723239
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloblastic leukemia with minimal myeloid differentiation (FAB AML-M0): a study of eleven cases.
Sempere A; Jarque I; Guinot M; Palau J; García R; Sanz GF; Gomis F; Pérez-Sirvent ML; Senent L; Sanz MA
Leuk Lymphoma; 1993 Dec; 12(1-2):103-8. PubMed ID: 8161925
[TBL] [Abstract][Full Text] [Related]
16. High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial.
Heil G; Mitrou PS; Hoelzer D; Freund M; Link H; Ehninger G; Steinke B; Ohl S; Wandt H; Fackler-Schwalbe E
Ann Hematol; 1995 Nov; 71(5):219-25. PubMed ID: 7492624
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
18. Proportion of blasts with a clear halo around nucleoli at the end of induction therapy of acute myeloid leukemia correlates with achievement of complete remission, remission duration and relapse.
Emura I; Chou T; Ishiguro T; Kakihara T; Naito M; Yoshizawa H; Arakawa M
Pathol Int; 1998 Jul; 48(7):526-35. PubMed ID: 9701015
[TBL] [Abstract][Full Text] [Related]
19. Repeated cycles of G-CSF-combined postremission chemotherapy for acute myeloid leukemia in a first complete remission: a pilot study.
Ogata K; An E; Kamikubo K; Yokose N; Tamura H; Yamada T; Gomi S; Dan K; Nomura T
Stem Cells; 1998; 16(4):280-7. PubMed ID: 9708450
[TBL] [Abstract][Full Text] [Related]
20. [Differentiating effect of the oral administration of vitamin D and vitamin A in acute myelocytic leukemia after BHAC-DMP therapy].
Yamane T; Furukawa Y; Inoue T; Sagawa H; Yokomatsu Y; Kishida T; Sasaki A; Kojima K; Sannomiya Y; Yoshikawa T
Rinsho Ketsueki; 1988 May; 29(5):765-8. PubMed ID: 3216506
[No Abstract] [Full Text] [Related]
[Next] [New Search]
